Jaguar Health (JAGX) Return on Sales (2015 - 2026)

Jaguar Health (JAGX) has 12 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.0%, up 5.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 2.0% YoY), and the FY2025 annual result was 0.05%, down 1.0% from the prior year.
• Return on Sales climbed to 0.0% in Q1 2026 per JAGX's latest filing, from 0.07% in the prior quarter.
• Over five years, Return on Sales peaked at 0.0% in Q1 2026 and troughed at 9.08% in Q1 2022.
• A 5-year average of 0.88% and a median of 0.04% in 2024 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2022 and 2023: Return on Sales plunged 899 bps in 2022, then surged 633 bps in 2023.
• A 5-year view of Return on Sales shows it stood at 2.57% in 2022, then surged by 98 bps to 0.04% in 2023, then increased by 28 bps to 0.03% in 2024, then sank by 146 bps to 0.07% in 2025, then jumped by 106 bps to 0.0% in 2026.
• Business Quant data shows JAGX's Return on Sales at 0.0% in Q1 2026, 0.07% in Q4 2025, and 0.03% in Q3 2025.